Rolipram: a specific phosphodiesterase 4 inhibitor with potential antipsychotic activity.
about
Distinct roles of PDE4 and PDE10A in the regulation of cAMP/PKA signaling in the striatumPhosphodiesterase 4 inhibition enhances the dopamine D1 receptor/PKA/DARPP-32 signaling cascade in frontal cortex.Realistic expectations of prepulse inhibition in translational models for schizophrenia research.Evaluating the antipsychotic profile of the preferential PDE10A inhibitor, papaverineStructures of the four subfamilies of phosphodiesterase-4 provide insight into the selectivity of their inhibitorsPsychiatric aspects of phosphodiesterases: An overview.Selective Phosphodiesterase 4B Inhibitors: A ReviewThe DISC locus in psychiatric illnessDISC1-binding proteins in neural development, signalling and schizophreniaInhibition of phosphodiesterase 4 reduces ethanol intake and preference in C57BL/6J miceDISC1: Structure, Function, and Therapeutic Potential for Major Mental IllnessGenetic and pharmacological evidence for schizophrenia-related Disc1 interaction with GSK-3.PDE4 inhibition enhances hippocampal synaptic plasticity in vivo and rescues MK801-induced impairment of long-term potentiation and object recognition memory in an animal model of psychosisDevelopmental etiology for neuroanatomical and cognitive deficits in mice overexpressing Galphas, a G-protein subunit genetically linked to schizophrenia.Sensorimotor gating in neurotensin-1 receptor null mice.Phosphodiesterase 11A in brain is enriched in ventral hippocampus and deletion causes psychiatric disease-related phenotypes.Strain differences in the gating-disruptive effects of apomorphine: relationship to gene expression in nucleus accumbens signaling pathwaysChronic Galphas signaling in the striatum increases anxiety-related behaviors independent of developmental effectsA novel rat strain with enhanced sensitivity to the effects of dopamine agonists on startle gating.Pivotal effects of phosphodiesterase inhibitors on myocyte contractility and viability in normal and ischemic hearts.Brain region-specific decrease in the activity and expression of protein kinase A in the frontal cortex of regressive autism.Identification of a potent new chemotype for the selective inhibition of PDE4Copy Number Variations in DISC1 and DISC1-Interacting Partners in Major Mental Illness.Disrupted in schizophrenia 1 and phosphodiesterase 4B: towards an understanding of psychiatric illness.Immature dentate gyrus: an endophenotype of neuropsychiatric disorders.Selective phosphodiesterase inhibitors: a promising target for cognition enhancement.Electroencephalographic and early communicative abnormalities in Brattleboro rats.Further Insights in the Binding Mode of Selective Inhibitors to Human PDE4D Enzyme Combining Docking and Molecular Dynamics.Genome-wide association study of patient-rated and clinician-rated global impression of severity during antipsychotic treatmentLeading compounds for the validation of animal models of psychopathology.The glutamatergic aspects of schizophrenia molecular pathophysiology: role of the postsynaptic density, and implications for treatmentNew pharmacotherapy options for noninfectious posterior uveitis.The phosphodiesterase-4 inhibitor roflumilast decreases ethanol consumption in C57BL/6J mice.PKA phosphorylation of NDE1 is DISC1/PDE4 dependent and modulates its interaction with LIS1 and NDEL1Abenquines A-D: aminoquinone derivatives produced by Streptomyces sp. strain DB634.The atypical anxiolytic drug, tofisopam, selectively blocks phosphodiesterase isoenzymes and is active in the mouse model of negative symptoms of psychosis.Design, synthesis, and structure-activity relationship, molecular modeling, and NMR studies of a series of phenyl alkyl ketones as highly potent and selective phosphodiesterase-4 inhibitors.Cyclic nucleotide signaling changes associated with normal aging and age-related diseases of the brain.Isolation, characterization and molecular 3D model of human GDE4, a novel membrane protein containing glycerophosphodiester phosphodiesterase domain.Critical role of nitric oxide in the modulation of prepulse inhibition in Swiss mice.
P2860
Q23909635-CCD996DE-215E-4CE0-B8F4-285BEF4CA830Q24633622-EFA201C2-C3F7-47B0-87CB-72884DD7F949Q24645703-C09C8F5D-2DAD-44D3-A900-A0D165563233Q24649503-EA214B4B-668F-4A20-850E-E06E31860286Q27647620-C7A127C4-AE3C-4AEB-8FC8-114185BB3983Q28078128-3046770A-EDF5-4BAD-9E5C-D1A7652EEA97Q28081071-1C071BCE-37CC-477D-B5C4-CAC9A2D303C6Q28251868-7DD7585E-B822-4740-BDB7-8E1182C32842Q28302106-B3D76358-0B5E-4EE1-8730-42DB660DC567Q28386651-1DEECBA3-49EB-4FC1-A572-3B56CDED5619Q28393891-6E7AF3F0-3111-4567-8658-A9CCDD41ACE2Q30408186-5B5031D8-13F0-485E-BDD3-6BF4422BBCCDQ30468797-231E1A38-EB57-43CB-A068-0890BB6DF565Q30469285-7644CAFE-416F-4757-B4A5-D97D157003D7Q30477911-F20ED64D-D8BE-4183-BC51-28E5C13D6D67Q30478804-89FCB3A9-8783-43C7-BADD-E2FF57FF7CFCQ30485498-5FAB9BA5-C0A9-426F-BBB7-0EF9A1DFCD0FQ30488915-B744B53C-DA5A-49C9-B027-82A14C6CE5A2Q30491996-7339CC34-63A9-46E3-BCC2-B3A7656D9E67Q33552229-C24B2A66-9DDE-46C3-B6DF-D108E0139EAAQ34016340-EB2EADE6-39A2-4BE7-BAE8-080154C9419CQ36499703-022C5222-10B0-4E45-A8D0-5DC22DEF36F8Q36915572-B445F099-87E4-43FC-8A4E-6437D3DBA471Q36933003-C4566DAA-AF42-4908-8CFA-59A5329957CCQ36960113-542309D5-A301-4CA9-84E7-212CA13E41F1Q37245947-D697D1DA-9F00-417D-8CF8-722306ABBFB8Q37344122-9A277C3B-021E-421C-B89C-EBC23FB86C5EQ37391836-1CF9A586-4B4C-48CB-B9DF-317EADA6BB11Q37581282-FD2BD4FA-0733-4942-A1E3-B85C26C4771DQ38128733-0A659F16-F9E0-402F-A232-629A94AD08BFQ38213709-895A1223-8245-4B95-B0A2-9CAC401AC2D1Q38253095-7C4E97AD-0097-461C-91EC-009907450B27Q38801216-BD473CDF-C092-47CB-8E1B-0482A6871D04Q39366533-CA931156-A422-4EFF-8EE1-54EA5140E7B7Q39440022-A897D76A-C013-45EF-90A1-7CFFAFBB955FQ41435708-77349DD5-152D-4FF1-8476-6E1E8A9E930FQ42002871-3EBAEC56-282F-46FA-9C10-78FBBA3B9D65Q45305673-92152C1C-C75A-4EA1-A866-48AC05BE0BD3Q46259216-A27A4CF9-71CE-405F-BACA-BA4FEFA7C4E8Q46986165-37555550-9A31-4AFB-8518-0E037532BB5C
P2860
Rolipram: a specific phosphodiesterase 4 inhibitor with potential antipsychotic activity.
description
2006 nî lūn-bûn
@nan
2006 թուականի Նոյեմբերին հրատարակուած գիտական յօդուած
@hyw
2006 թվականի նոյեմբերին հրատարակված գիտական հոդված
@hy
2006年の論文
@ja
2006年論文
@yue
2006年論文
@zh-hant
2006年論文
@zh-hk
2006年論文
@zh-mo
2006年論文
@zh-tw
2006年论文
@wuu
name
Rolipram: a specific phosphodiesterase 4 inhibitor with potential antipsychotic activity
@nl
Rolipram: a specific phosphodiesterase 4 inhibitor with potential antipsychotic activity.
@ast
Rolipram: a specific phosphodiesterase 4 inhibitor with potential antipsychotic activity.
@en
type
label
Rolipram: a specific phosphodiesterase 4 inhibitor with potential antipsychotic activity
@nl
Rolipram: a specific phosphodiesterase 4 inhibitor with potential antipsychotic activity.
@ast
Rolipram: a specific phosphodiesterase 4 inhibitor with potential antipsychotic activity.
@en
prefLabel
Rolipram: a specific phosphodiesterase 4 inhibitor with potential antipsychotic activity
@nl
Rolipram: a specific phosphodiesterase 4 inhibitor with potential antipsychotic activity.
@ast
Rolipram: a specific phosphodiesterase 4 inhibitor with potential antipsychotic activity.
@en
P2093
P2860
P50
P1433
P1476
Rolipram: a specific phosphodiesterase 4 inhibitor with potential antipsychotic activity
@en
P2093
P2860
P304
P356
10.1016/J.NEUROSCIENCE.2006.09.026
P407
P577
2006-11-01T00:00:00Z